|
 |
 |
|
 |
 |
|
OCTOBER
5 - 6, 2007
13th Annual Perspectives in Breast Cancer
Boston, Massachusetts
The Colonnade Boston
Chairs:
Edith A. Perez, MD
Mayo Clinic
Jacksonville, Florida
Abram Recht, MD
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts
Click
here to register for this program |
 |
|
I N V I T A T I O N |
 |
|
|
Dear Colleague
It is with great pleasure and enthusiasm that we invite you to attend the 13th Annual Perspectives in Breast Cancer Program. Over the past thirteen years, this meeting has become a dynamic forum for leaders in breast cancer research and patient care to increase their knowledge and share their challenges and successes in disease management and patient care.
It is common knowledge that breast cancer is the second leading cause of cancer mortality. Nearly 300,000 women in the United States will be diagnosed with some form of the disease this year alone. Significant media and medical attention to this disease has stimulated a large body of research dedicated to the detection, diagnosis, treatment and prevention of breast cancer, and as a result, our knowledge of the etiology and mechanisms of the disease has unfolded at a highly accelerated pace.
The wealth of available data in this rapidly evolving field makes it difficult for practitioners to weed out quality research and pertinent data. Thus, this conference is designed to provide you, as a practicing clinician, with a comprehensive overview of this important and evolving field. Our panel, which is composed of leading clinicians and researchers involved with breast cancer, will provide the latest information on state-of-the-art developments from the leading cancer centers and academic institutions.
Please join us this fall in Boston for a rewarding professional update!
Sincerely,
Edith A. Perez, MD
Abram Recht, MD
Chairs |
|
|
|
F A C U L T Y |
|
|
Harold J. Burstein, MD
Dana Farber Cancer Institute
Boston, Massachusetts
Maura N. Dickler, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
Deborah Feigel, PA
Mayo Clinic
Jacksonville, Florida
Kevin Fox, MD
University of Pennsylvania
Philadelphia, Pennsylvania
Richard J. Gray, MD
Mayo Clinic
Scottsdale, Arizona
Charles L. Loprinzi, MD
Mayo Clinic
Rochester, Minnesota
Lisa
Newman, MD
University
of Michigan
Ann
Arbor, Michigan
Ruth
O’Regan, MD
Winship
Cancer Institute
Emory University
Atlanta,
Georgia
|
Frances Palmieri, RN, MSN, OCN
Mayo Clinic
Jacksonville, Florida
Edith A. Perez, MD
Mayo Clinic
Jacksonville, Florida
Abram Recht, MD
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts
Lupe G. Salazar, MD
University of Washington
Seattle, Washington
Heidi Schulz, RN, OCN
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts
Joseph A. Sparano, MD
Albert Einstein College of Medicine
Bronx, New York
|
Vered Stearns, MD
Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins
Baltimore, Maryland
Alisha Stein, RN, MSN, RCN, OCN
Cancer Research Network
Boca Raton, Florida
Alphonse Taghian, MD, PhD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Brittany Thomas, MS, CGC
Mayo Clinic
Rochester, Minnesota
Frank A. Vicini, MD
William Beaumont Hospital
Royal Oak, Michigan
Victor G. Vogel, MD
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
|
|
|
|
S C I E N T I F I C A G E N D A |
|
|
| Friday, October 5, 2007
Pre-conference program: Challenges
in breast cancer nursing
8:30 am
Welcome
8:35 am
Genetics
of breast cancer risk
Brittany
Thomas, MS, CGC
9:00 am
Questions
9:05
am
Surgical
advances and management of complications
Deborah
Feigel, PA
9:30
am
Questions
9:35
am
Break
9:50
am
Breast
cancer: Oral drug adherence
Frances Palmieri, RN, MSN,
OCN
10:15
am
Questions
10:20
am
Nursing
care of the patient receiving radiation
therapy
Heidi Schulz, RN, OCN
10:45
am
Questions
10:50
am
The impact
of breast cancer and its treatment
on families
Alisha Stein
RN, MSN, OCN
11:15
am
Questions
11:20
am
Lunch
General
Sessions
Welcome and introductory lecture
12:00
pm
Welcome
and introduction
Session I: Breast cancer: Prevention,
detection, and prognosis
12:05
pm
Chemoprevention
strategies: assessing risk of breast
cancer and choice of agent
Victor G. Vogel, MD
12:25
pm
Genetic
profiling in breast cancer
Joseph
A. Sparano, MD
12:45
pm
Vaccines: novel tools to prevent breast
cancer recurrence
Lupe
G. Salazar, MD
1:05
pm
Panel
discussion
Session II: Surgery/Radiotherapy
1:15
pm
Breast-conserving
therapy after neoadjuvant chemotherapy
Lisa
Newman, MD
1:45
pm
Questions
1:55
pm
Break
2:15
pm
Radiation
in DCIS: Weighing the risk and benefits
Abram Recht,
MD
2:40
pm
Accelerated
partial breast irradiation
Frank
A Vicini, MD
3:05
pm
Alternatives
to axillary dissection for patients with
positive sentinel nodes: interactive
cases
Abram
Recht, MD
3:35
pm
Micrometastases: evaluating their significance
and management
Richard
J. Gray, MD
4:00
pm
Panel
discussion
4:15
pm
Adjourn
Saturday, October 6, 2007
8:30
am
Welcome
to day two
Session III: Early and locally advanced
disease
8:35
am
Optimizing
taxane regimens in node-positive patients
Harold
J Burstein, MD
9:00
am
Adjuvant
hormonal therapy in postmenopausal women
Harold
J Burstein, MD
9:25
am
Current guidelines and new strategies
for treating early HER2 positive patients
Edith
A. Perez, MD
9:50
am
New
studies of anti-angiogenesis agents in
early breast cancer
Maura
N. Dickler, MD
10:15
am
Pharmacogenomics
of tamoxifen and aromatase inhibitor
therapy
Vered
Stearns
10:40
am
Panel
discussion
11:00
am
Lunch
Session
IV: Disease management
12:00
pm
Managing
the side effects of hormonal therapy
Charles L. Loprinzi, MD
12:25
pm
Treatment-related
cardiac toxicity
Alphonse Taghian,
MD, PhD
12:50
pm
Panel discussion
1:10
pm
Break
Session V: Metastatic and inflammatory
breast cancer
1:25
pm
Update
on novel targeted therapies as monotherapeutic
agents or with chemotherapy
for metastatic/refractory disease
Kevin
Fox, MD
1:50
pm
Lapatinib
for inflammatory and trastuzumab-resistant
breast cancer
Kevin
Fox, MD
2:15
pm
Role of hormonal therapy as single
agent or in combination with other agents
in advanced disease
Ruth
O'Regan, MD2:40
pm
Panel
discussion
3:00
pm
Closing
statements and adjourn |
|
|
|
C O N T I N U I N G M E D I C A L
E D U C A T I O N |
|
|
|
Physicians
Imedex®,
LLC is accredited by the Accreditation Council for Continuing Medical Education
to provide continuing medical education for physicians.
Imedex,
LLC designates this educational activity
for a maximum of 11.5 category 1 credits
toward the AMA Physician’s Recognition
Award. Each
physician should claim only those credits
that he/she actually spent in the activity.
Nurses
This program (1007) has been approved by an AACN Certification Corporation-approved provider (Provider #00013328) under established AACN Certification Corporation guidelines for a maximum of 12.5 contact hours, CERP Category A. |
|
|
| W H O S H O U L D A T T E N
D ? |
|
|
|
This educational program is intended for medical oncologists, surgical oncologists, primary care physicians, nurses, other practicing clinicians, and healthcare administrators who are interested and/or involved in the management of breast cancer. No specialized knowledge or skills other than a general familiarity with cancer and its treatment is required for successful participation in this program.
|
|
|
| O B J E C T I V E S |
|
|
| After successful completion of this course, participants should be able to:
- Identify patients who would benefit from chemoprevention and differentiate the risks and benefits of various agents
- Select the most appropriate techniques for screening, diagnosis, and initial evaluation of breast cancer
- Identify the latest and most important prognostic and predictive factors in breast cancer
- Identify and explain the appropriate therapeutic options for patients with ductal carcinoma in situ, early stage or metastatic cancer
- Describe the latest developments in surgery, radiation therapy, and systemic therapy for the treatment of breast cancer
- Discuss effective management of side effects and toxicities secondary to oncological therapies
- Evaluate and integrate recent clinical trial data regarding hormonal and targeted therapies into a cohesive therapeutic plan for patients
- List the most promising future strategies for the management of breast cancer
|
|
|
|
| R E G I S T R A T I O N |
|
|
| REGISTRATION FEES
Physicians
Discounted . . . . . . . . . . . . . . . . . . . . .$195
If payment received by August 9, 2007
Regular . . . . . . . . . . . . . . . . . . . . . . . $295
If payment received by September 27, 2007
Full/Onsite . . . . . . . . . . . . . . . . . . . . . $395
If payment received after September 27, 2007
Group discount*. . . . . . . . . . . . . . . . . . -$50
(*Physicians only; Cannot be combined with any other discounts)
Nurses/Residents/Students* . . . . . . . . . $75
(*proof of eligibility must accompany registration)
To Register: You may register online by September 27, 2007 at www.imedex.com or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting.
To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.
Group Discounts: Each one of multiple registrants from the same institute or practice each receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts are not available for Nurse/Resident/ Student rates.
Payment: To pre-register, registration and payment must be received no later than September 27, 2007. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the program is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card, check, or wire transfer. Checks should be payable to Imedex. To pay via wire transfer, you must add $25 to each wire transaction to cover bank charges. Include the full name of the attendee and the name of the conference: 13th Perspectives in Breast Cancer #286. An attendee is not registered until full payment is received.
Wire to: Bank of America, ABA: 0260.0959.3, Account Info: Imedex, Inc., Account: 0000.0106.3308. If the wire originates outside the United States, please add this additional information: Clearing Bank: Bank of America, New York, Swift Code: BOFAUS3N, Clearing Account: 6550305831.
Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.
Cancellation: For registration fees to be refunded, written notice of cancellation must be received at Imedex no later than September 27, 2007. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after September 27, 2007.
Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event program content is subject to change without notice.
|
|
|
| G E N E R A L I N F O R M A T I O N |
|
|
Discounted Airfares
Contact conference travel agent, Age of Travel, for assistance with your travel needs. Age of Travel can also accommodate pre- and post-conference extensions.
Tel.: 1 (800) 523 4954 or +1 (404) 591 7120
Email: imedex@ageoftravel.com
Conference Location and Registration
The Colonnade Boston
120 Huntington Avenue, Boston, MA 02116
Tel.: +1 (617) 424 7000, Fax: +1 (617) 424 1717
www.colonnadehotel.com
The Registration and Information Desk will be staffed:
Friday, October 5, 2007 . . . . . . . . 7:30 am – 4:30 pm
Saturday, October 6, 2007 . . . . . . .7:30 am – 3:00 pm |
|
|
|
H O T E L A C
C O M M O D A T I O N S |
|
|
|
The Colonnade Boston
120 Huntington Avenue, Boston, MA 02116
Tel.: +1 (617) 424 7000, Fax: +1 (617) 424 1717
www.colonnadehotel.com
Nestled among Boston’s finest cultural venues and most exciting shops in the heart of Boston’s historic Back Bay, The Colonnade Hotel is an independent Boston luxury hotel with 285 elegantly appointed rooms and luxury suites.
In April 2006, The Colonnade Hotel, Boston completed a multi-million dollar renovation of its windows that includes every guest room. All rooms now feature sound-proof floor to ceiling windows that open to offer fresh air, coupled with better energy efficiency due to double panes and advanced tint technology.
This downtown Boston hotel is known not only for its superb service in a luxury environment but also for its cutting edge technology like wireless Internet and High Speed Internet access available throughout the entire hotel.
For the convenience of attendees, a limited number of rooms have been reserved until Thursday, September 13, 2007 at a discounted rate of $279.00 single/double occupancy, plus tax, currently at 12.45%. This rate is not guaranteed outside the conference dates or after Thursday, September 13, 2007.
To reserve your room please contact The Colonnade Boston reservations department at +1 (617) 424 7000 or visit the hotel’s website at www.colonnadehotel.com. To receive the group rate, callers must identify themselves as being with the 13th Annual Perspectives in Breast Cancer group. Internet users must click on “Make a Reservation” tab and enter the meeting promotional code: IMEDEX. Reservation requests received after Thursday, September 13, 2007 may not be guaranteed the group rate.
|
|
|
| O R G A N I Z E R |
|
|
|
|
©
2007 Imedex®, LLC |
|
